A pilot study transitioning children onto levetiracetam monotherapy to improve language dysfunction associated with benign rolandic epilepsy

Research output: Contribution to journalArticle

Abstract

Benign rolandic epilepsy (BRE) and Landau-Kleffner syndrome (LKS) are similar epilepsy syndromes with sleep-accentuated epileptiform activity, sporadic seizures, and language dysfunction. Levetiracetam has been associated with improved language function in LKS and seizure reduction in BRE. We hypothesized levetiracetam would improve language function in children with BRE. A pilot study was performed with six children (aged 6-12) with BRE and evidence of impaired auditory comprehension and verbal memory. Children were transitioned from their current anticonvulsant to 40 mg/kg/day levetiracetam over a 2-week period and retested at 6 months. At 6 months, three of four children with baseline auditory comprehension impairments performed normally (P = 0.06), and five had improved auditory verbal memory (P = 0.08). Seizures improved in five, decreasing from 2.7 to 1.0 seizure per 6 months (P = 0.11). Results from this pilot study suggest that levetiracetam may have a beneficial effect on language in children with BRE.

Original languageEnglish (US)
Pages (from-to)514-517
Number of pages4
JournalEpilepsy and Behavior
Volume11
Issue number4
DOIs
StatePublished - Dec 2007

Fingerprint

etiracetam
Rolandic Epilepsy
Language
Seizures
Landau-Kleffner Syndrome
Child Language
Anticonvulsants
Epilepsy
Sleep

Keywords

  • Benign rolandic
  • Centrotemporal
  • Children
  • Language
  • Levetiracetam
  • Seizures

ASJC Scopus subject areas

  • Clinical Neurology
  • Behavioral Neuroscience
  • Neurology

Cite this

@article{91e54e85f3614ef6a00a717cb594b487,
title = "A pilot study transitioning children onto levetiracetam monotherapy to improve language dysfunction associated with benign rolandic epilepsy",
abstract = "Benign rolandic epilepsy (BRE) and Landau-Kleffner syndrome (LKS) are similar epilepsy syndromes with sleep-accentuated epileptiform activity, sporadic seizures, and language dysfunction. Levetiracetam has been associated with improved language function in LKS and seizure reduction in BRE. We hypothesized levetiracetam would improve language function in children with BRE. A pilot study was performed with six children (aged 6-12) with BRE and evidence of impaired auditory comprehension and verbal memory. Children were transitioned from their current anticonvulsant to 40 mg/kg/day levetiracetam over a 2-week period and retested at 6 months. At 6 months, three of four children with baseline auditory comprehension impairments performed normally (P = 0.06), and five had improved auditory verbal memory (P = 0.08). Seizures improved in five, decreasing from 2.7 to 1.0 seizure per 6 months (P = 0.11). Results from this pilot study suggest that levetiracetam may have a beneficial effect on language in children with BRE.",
keywords = "Benign rolandic, Centrotemporal, Children, Language, Levetiracetam, Seizures",
author = "Kossoff, {Eric H} and Los, {Jenna G.} and Boatman, {Dana F}",
year = "2007",
month = "12",
doi = "10.1016/j.yebeh.2007.07.011",
language = "English (US)",
volume = "11",
pages = "514--517",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - A pilot study transitioning children onto levetiracetam monotherapy to improve language dysfunction associated with benign rolandic epilepsy

AU - Kossoff, Eric H

AU - Los, Jenna G.

AU - Boatman, Dana F

PY - 2007/12

Y1 - 2007/12

N2 - Benign rolandic epilepsy (BRE) and Landau-Kleffner syndrome (LKS) are similar epilepsy syndromes with sleep-accentuated epileptiform activity, sporadic seizures, and language dysfunction. Levetiracetam has been associated with improved language function in LKS and seizure reduction in BRE. We hypothesized levetiracetam would improve language function in children with BRE. A pilot study was performed with six children (aged 6-12) with BRE and evidence of impaired auditory comprehension and verbal memory. Children were transitioned from their current anticonvulsant to 40 mg/kg/day levetiracetam over a 2-week period and retested at 6 months. At 6 months, three of four children with baseline auditory comprehension impairments performed normally (P = 0.06), and five had improved auditory verbal memory (P = 0.08). Seizures improved in five, decreasing from 2.7 to 1.0 seizure per 6 months (P = 0.11). Results from this pilot study suggest that levetiracetam may have a beneficial effect on language in children with BRE.

AB - Benign rolandic epilepsy (BRE) and Landau-Kleffner syndrome (LKS) are similar epilepsy syndromes with sleep-accentuated epileptiform activity, sporadic seizures, and language dysfunction. Levetiracetam has been associated with improved language function in LKS and seizure reduction in BRE. We hypothesized levetiracetam would improve language function in children with BRE. A pilot study was performed with six children (aged 6-12) with BRE and evidence of impaired auditory comprehension and verbal memory. Children were transitioned from their current anticonvulsant to 40 mg/kg/day levetiracetam over a 2-week period and retested at 6 months. At 6 months, three of four children with baseline auditory comprehension impairments performed normally (P = 0.06), and five had improved auditory verbal memory (P = 0.08). Seizures improved in five, decreasing from 2.7 to 1.0 seizure per 6 months (P = 0.11). Results from this pilot study suggest that levetiracetam may have a beneficial effect on language in children with BRE.

KW - Benign rolandic

KW - Centrotemporal

KW - Children

KW - Language

KW - Levetiracetam

KW - Seizures

UR - http://www.scopus.com/inward/record.url?scp=36549081326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549081326&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2007.07.011

DO - 10.1016/j.yebeh.2007.07.011

M3 - Article

C2 - 17936689

AN - SCOPUS:36549081326

VL - 11

SP - 514

EP - 517

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

IS - 4

ER -